Final answer:
The profit per unit for Daraprim before the price increase by Turing Pharmaceuticals cannot be determined without access to the company's confidential financial records at that time.
Step-by-step explanation:
The profit per unit for the drug Daraprim before Turing Pharmaceuticals increased the price is not typically public information. This data involves internal calculations of the cost of production, distribution, marketing, research and development expenses, and other factors specific to the company that owned Daraprim at the time. In most cases, such specifics are not disclosed to the public and are considered proprietary business information. Therefore, without access to the financial records of the company prior to Turing Pharmaceuticals' acquisition and price increase, the precise profit per unit for Daraprim cannot be accurately determined.